{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:56Z","timestamp":1793134136321,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1174523"],"award-info":[{"award-number":["1174523"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Population mammographic screening for breast cancer has led to large increases in the diagnosis and treatment of ductal carcinoma in situ (DCIS). Active surveillance has been proposed as a management strategy for low-risk DCIS to mitigate against potential overdiagnosis and overtreatment. However, clinicians and patients remain reluctant to choose active surveillance, even within a trial setting. Re-calibration of the diagnostic threshold for low-risk DCIS and\/or use of a label that does not include the word \u2018cancer\u2019 might encourage the uptake of active surveillance and other conservative treatment options. We aimed to identify and collate relevant epidemiological evidence to inform further discussion on these ideas.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed and EMBASE databases for low-risk DCIS studies in four categories: (1) natural history; (2) subclinical cancer found at autopsy; (3) diagnostic reproducibility (two or more pathologist interpretations at a single time point); and (4) diagnostic drift (two or more pathologist interpretations at different time points). Where we identified a pre-existing systematic review, the search was restricted to studies published after the inclusion period of the review. Two authors screened records, extracted data, and performed risk of bias assessment. We undertook a narrative synthesis of the included evidence within each category.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Natural History (<jats:italic>n<\/jats:italic>\u2009=\u200911): one systematic review and nine primary studies were included, but only five provided evidence on the prognosis of women with low-risk DCIS. These studies reported that women with low-risk DCIS had comparable outcomes whether or not they had surgery. The risk of invasive breast cancer in patients with low-risk DCIS ranged from 6.5% (7.5\u00a0years) to 10.8% (10\u00a0years). The risk of dying from breast cancer in patients with low-risk DCIS ranged from 1.2 to 2.2% (10\u00a0years). Subclinical cancer at autopsy (<jats:italic>n<\/jats:italic>\u2009=\u20091): one systematic review of 13 studies estimated the mean prevalence of subclinical in situ breast cancer to be 8.9%. Diagnostic reproducibility (<jats:italic>n<\/jats:italic>\u2009=\u200913): two systematic reviews and 11 primary studies found at most moderate agreement in differentiating low-grade DCIS from other diagnoses. Diagnostic drift: no studies found.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Epidemiological evidence supports consideration of relabelling and\/or recalibrating diagnostic thresholds for low-risk DCIS. Such diagnostic changes would need agreement on the definition of low-risk DCIS and improved diagnostic reproducibility.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06934-y","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T13:03:31Z","timestamp":1681909411000},"page":"415-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Should low-risk DCIS lose the cancer label? An evidence review"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7706","authenticated-orcid":false,"given":"Tara","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R.","family":"Semsarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala","family":"Pathmanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy J. L.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"12","key":"6934_CR1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, Van Leeuwen-Stok AE, Skinner VP, Dif N et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ\u2014The LORD study. Eur J Cancer 51(12):1497\u20131510","journal-title":"Eur J Cancer"},{"issue":"12","key":"6934_CR2","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ryser MD, Partridge AH, Thompson AM, Thomas JS, Wesseling J et al (2017) Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol 24(12):3534\u20133540","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"6934_CR3","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D et al (2019) The COMET (comparison of operative versus monitoring and endocrine therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9(3):e026797","journal-title":"BMJ Open"},{"issue":"5","key":"6934_CR4","doi-asserted-by":"crossref","first-page":"dvj372","DOI":"10.1093\/jnci\/djv372","volume":"108","author":"MD Ryser","year":"2016","unstructured":"Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES (2016) Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst 108(5):dvj372","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"6934_CR5","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","volume":"381","author":"HG Welch","year":"2019","unstructured":"Welch HG, Kramer BS, Black WC (2019) Epidemiologic signatures in cancer. N Engl J Med 381(14):1378\u20131386","journal-title":"N Engl J Med"},{"issue":"9","key":"6934_CR6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/ans.16970","volume":"91","author":"S Omling","year":"2021","unstructured":"Omling S, Houssami N, McGeechan K, Zackrisson S, Jacklyn G, Walters D et al (2021) The management of women with ductal carcinoma in situ of the breast in Australia and New Zealand between 2007 and 2016. ANZ J Surg 91(9):1784\u20131791","journal-title":"ANZ J Surg"},{"issue":"10","key":"6934_CR7","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S1470-2045(16)30367-9","volume":"17","author":"JR Benson","year":"2016","unstructured":"Benson JR, Jatoi I, Toi M (2016) Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol 17(10):e442\u2013e451","journal-title":"Lancet Oncol"},{"issue":"3","key":"6934_CR8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2015.5026","volume":"2","author":"L Fallowfield","year":"2016","unstructured":"Fallowfield L, Francis A (2016) Overtreatment of low-grade ductal carcinoma in situ. JAMA Oncol 2(3):382\u2013383","journal-title":"JAMA Oncol"},{"issue":"Suppl 3","key":"6934_CR9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1245\/s10434-017-6174-y","volume":"24","author":"D Rea","year":"2017","unstructured":"Rea D, Francis A, Wallis M, Thomas J, Bartlett J, Bowden S et al (2017) Confusion over differences in registration and randomization criteria for the LORIS (Low-Risk DCIS) trial. Ann Surg Oncol 24(Suppl 3):566\u2013567","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"6934_CR10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyx059","volume":"47","author":"C Kanbayashi","year":"2017","unstructured":"Kanbayashi C, Iwata H (2017) Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol 47(8):671\u2013677","journal-title":"Jpn J Clin Oncol"},{"issue":"5S","key":"6934_CR11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","volume":"16","author":"PH Carroll","year":"2018","unstructured":"Carroll PH, Mohler JL (2018) NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw 16(5S):620\u2013623","journal-title":"J Natl Compr Canc Netw"},{"key":"6934_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS17-OT3-08-01","author":"L Fallowfield","year":"2018","unstructured":"Fallowfield L, Matthews L, Jenkins V, May S, Francis A, Rae D et al (2018) Abstract OT3\u201308\u201301: interview data from women contemplating LORIS trial entry during the feasibility study. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS17-OT3-08-01","journal-title":"Cancer Res"},{"key":"6934_CR13","unstructured":"Hersch J, Nickel B, Dixon A, Jansen J, Saunders C, Houssami N, et al., editors. Treating (or Monitoring?) Low-risk ductal carcinoma in situ (DCIS): Focus groups about women\u2019s views. 42nd annual meeting of the society for medical decision making; 2020."},{"key":"6934_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.breast.2020.09.002","volume":"54","author":"B Nickel","year":"2020","unstructured":"Nickel B, McCaffery K, Houssami N, Jansen J, Saunders C, Spillane A et al (2020) Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): qualitative interview study. Breast 54:99\u2013105","journal-title":"Breast"},{"issue":"6","key":"6934_CR15","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","volume":"15","author":"LJ Esserman","year":"2014","unstructured":"Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15(6):e234\u2013e242","journal-title":"Lancet Oncol"},{"key":"6934_CR16","doi-asserted-by":"crossref","first-page":"k3322","DOI":"10.1136\/bmj.k3322","volume":"362","author":"B Nickel","year":"2018","unstructured":"Nickel B, Moynihan R, Barratt A, Brito JP, McCaffery K (2018) Renaming low risk conditions labelled as cancer. BMJ (Clin Res ed) 362:k3322","journal-title":"BMJ (Clin Res ed)"},{"key":"6934_CR17","doi-asserted-by":"crossref","first-page":"k4699","DOI":"10.1136\/bmj.k4699","volume":"364","author":"LJ Esserman","year":"2019","unstructured":"Esserman LJ, Varma M (2019) Should we rename low risk cancers? BMJ (Clin Res ed) 364:k4699","journal-title":"BMJ (Clin Res ed)"},{"key":"6934_CR18","doi-asserted-by":"crossref","first-page":"e008094","DOI":"10.1136\/bmjopen-2015-008094","volume":"5","author":"K McCaffery","year":"2015","unstructured":"McCaffery K, Nickel B, Moynihan R, Hersch J, Teixeira-Pinto A, Irwig L et al (2015) How different terminology for ductal carcinoma in situ impacts women\u2019s concern and treatment preferences: a randomised comparison within a national community survey. BMJ Open 5:e008094","journal-title":"BMJ Open"},{"issue":"7","key":"6934_CR19","doi-asserted-by":"crossref","first-page":"e014129","DOI":"10.1136\/bmjopen-2016-014129","volume":"7","author":"B Nickel","year":"2017","unstructured":"Nickel B, Barratt A, Copp T, Moynihan R, McCaffery K (2017) Words do matter: a systematic review on how different terminology for the same condition influences management preferences. BMJ Open 7(7):e014129","journal-title":"BMJ Open"},{"issue":"5","key":"6934_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.breast.2015.08.004","volume":"24","author":"B Nickel","year":"2015","unstructured":"Nickel B, Barratt A, Hersch J, Moynihan R, Irwig L, McCaffery K (2015) How different terminology for ductal carcinoma in situ (DCIS) impacts women\u2019s concern and management preferences: a qualitative study. Breast 24(5):673\u2013679","journal-title":"Breast"},{"issue":"6","key":"6934_CR21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamaoncol.2019.0054","volume":"5","author":"PR Dixon","year":"2019","unstructured":"Dixon PR, Tomlinson G, Pasternak JD, Mete O, Bell CM, Sawka AM et al (2019) The role of disease label in patient perceptions and treatment decisions in the setting of low-risk malignant neoplasms. JAMA Oncol 5(6):817\u2013823","journal-title":"JAMA Oncol"},{"issue":"19","key":"6934_CR22","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1001\/jamainternmed.2013.8405","volume":"173","author":"ZB Omer","year":"2013","unstructured":"Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM (2013) Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med 173(19):1830\u20131831","journal-title":"JAMA Intern Med"},{"key":"6934_CR23","first-page":"i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clin Res ed) 355:i4919","journal-title":"BMJ (Clin Res ed)"},{"issue":"9","key":"6934_CR24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C et al (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65(9):934\u2013939","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"6934_CR25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529\u2013536","journal-title":"Ann Intern Med"},{"issue":"8","key":"6934_CR26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jclinepi.2009.10.002","volume":"63","author":"NP Lucas","year":"2010","unstructured":"Lucas NP, Macaskill P, Irwig L, Bogduk N (2010) The development of a quality appraisal tool for studies of diagnostic reliability (QAREL). J Clin Epidemiol 63(8):854\u2013861","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"6934_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97(2):135\u2013144","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6934_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-020-06042-1","volume":"187","author":"D Byng","year":"2021","unstructured":"Byng D, Ret\u00e8l VP, Schaapveld M, Wesseling J, van Harten WH (2021) Treating (low-risk) DCIS patients: what can we learn from real-world cancer registry evidence? Breast Cancer Res Treat 187(1):187\u2013196","journal-title":"Breast Cancer Res Treat"},{"key":"6934_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41523-020-00199-0","volume":"6","author":"I Akushevich","year":"2020","unstructured":"Akushevich I, Yashkin AP, Greenup RA, Hwang ES (2020) A medicare-based comparative mortality analysis of active surveillance in older women with DCIS. NPJ breast cancer 6:57","journal-title":"NPJ breast cancer"},{"issue":"9","key":"6934_CR30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R et al (2019) Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst 111(9):952\u2013960","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6934_CR31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamasurg.2015.0876","volume":"150","author":"Y Sagara","year":"2015","unstructured":"Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT et al (2015) Survival benefit of breast surgery for low-grade ductal carcinoma in situ a population-based cohort study. JAMA Surg 150(8):739\u2013745","journal-title":"JAMA Surg"},{"key":"6934_CR32","first-page":"m1570","volume":"369","author":"GS Mannu","year":"2020","unstructured":"Mannu GS, Wang Z, Broggio J, Charman J, Cheung S, Kearins O et al (2020) Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988\u20132014: population based observational cohort study. BMJ (Clin Res ed) 369:m1570","journal-title":"BMJ (Clin Res ed)"},{"issue":"1","key":"6934_CR33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clon.2020.07.007","volume":"33","author":"M Co","year":"2021","unstructured":"Co M, Ngan RKC, Mang OWK, Tam AHP, Wong KH, Kwong A (2021) Long-term survival outcomes of \u201clow risk\u201d ductal carcinoma in situ from a territory-wide cancer registry. Clin Oncol 33(1):40\u201345","journal-title":"Clin Oncol"},{"issue":"4","key":"6934_CR34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejso.2017.12.007","volume":"44","author":"AJ Maxwell","year":"2018","unstructured":"Maxwell AJ, Dodwell DJ, Pinder SE, Wallis MG, Thompson AM, Thompson A et al (2018) Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol 44(4):429\u2013435","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"6934_CR35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.acra.2017.05.017","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ghate SV, Hwang ES, Soo MS (2017) Imaging features of patients undergoing active surveillance for ductal carcinoma in situ. Acad Radiol 24(11):1364\u20131371","journal-title":"Acad Radiol"},{"issue":"6","key":"6934_CR36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.breast.2011.06.001","volume":"20","author":"AF Meyerson","year":"2011","unstructured":"Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN et al (2011) Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast 20(6):529\u2013533","journal-title":"Breast"},{"issue":"1","key":"6934_CR37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/s12885-017-3808-1","volume":"17","author":"ET Thomas","year":"2017","unstructured":"Thomas ET, Del Mar C, Glasziou P, Wright G, Barratt A, Bell KJL (2017) Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis. BMC Cancer 17(1):808","journal-title":"BMC Cancer"},{"issue":"4","key":"6934_CR38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/jclinpath-2016-204184","volume":"70","author":"N Segnan","year":"2017","unstructured":"Segnan N, Minozzi S, Ponti A, Bellisario C, Balduzzi S, Gonz\u00e1lez-Lorenzo M et al (2017) Estimate of false-positive breast cancer diagnoses from accuracy studies: a systematic review. J Clin Pathol 70(4):282\u2013294","journal-title":"J Clin Pathol"},{"issue":"11","key":"6934_CR39","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2015.1405","volume":"313","author":"JG Elmore","year":"2015","unstructured":"Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN et al (2015) Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 313(11):1122\u20131132","journal-title":"JAMA"},{"issue":"5","key":"6934_CR40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/ajcp\/aqaa077","volume":"154","author":"MR Van Bockstal","year":"2020","unstructured":"Van Bockstal MR, Berli\u00e8re M, Duhoux FP, Galant C (2020) Interobserver variability in ductal carcinoma in situ of the breast. Am J Clin Pathol 154(5):596\u2013609","journal-title":"Am J Clin Pathol"},{"key":"6934_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8777","author":"E Mercan","year":"2019","unstructured":"Mercan E, Mehta S, Bartlett J, Shapiro LG, Weaver DL, Elmore JG (2019) Assessment of machine learning of breast pathology structures for automated differentiation of breast cancer and high-risk proliferative lesions. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8777","journal-title":"JAMA Netw Open"},{"key":"6934_CR42","first-page":"106689691985454","volume":"2019","author":"L Qiu","year":"2019","unstructured":"Qiu L, Mais DD, Nicolas M, Nanyes J, Kist K, Nazarullah A (2019) Diagnosis of papillary breast lesions on core needle biopsy: upgrade rates and interobserver variability. Int J Surg Pathol 2019:1066896919854543","journal-title":"Int J Surg Pathol"},{"key":"6934_CR43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbi.2017.01.004","volume":"66","author":"TT Brunye","year":"2017","unstructured":"Brunye TT, Mercan E, Weaver DL, Elmore JG (2017) Accuracy is in the eyes of the pathologist: The visual interpretive process and diagnostic accuracy with digital whole slide images. J Biomed Inform 66:171\u2013179","journal-title":"J Biomed Inform"},{"issue":"5","key":"6934_CR44","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1245\/s10434-016-5695-0","volume":"24","author":"SL Jackson","year":"2017","unstructured":"Jackson SL, Frederick PD, Pepe MS, Nelson HD, Weaver DL, Allison KH et al (2017) Diagnostic reproducibility: what happens when the same pathologist interprets the same breast biopsy specimen at two points in time? Ann Surg Oncol 24(5):1234\u20131241","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6934_CR45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1066896916662154","volume":"25","author":"G Tozbikian","year":"2017","unstructured":"Tozbikian G, Brogi E, Vallejo CE, Giri D, Murray M, Catalano J et al (2017) Atypical ductal hyperplasia bordering on ductal carcinoma in situ. Int J Surg Pathol 25(2):100\u2013107","journal-title":"Int J Surg Pathol"},{"issue":"2","key":"6934_CR46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/tbj.12708","volume":"23","author":"P Trocchi","year":"2017","unstructured":"Trocchi P, Holzhausen HJ, Loning T, Bocker W, Schmidt-Pokrzywniak A, Thomssen C et al (2017) Intraobserver agreement on histopathologic evaluations of core breast biopsies. Breast J 23(2):215\u2013219","journal-title":"Breast J"},{"issue":"4","key":"6934_CR47","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/his.13117","volume":"70","author":"EA Rakha","year":"2017","unstructured":"Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH, Pinder SE et al (2017) Diagnostic concordance of breast pathologists: lessons from the national health service breast screening programme pathology external quality assurance scheme. Histopathology 70(4):632\u2013642","journal-title":"Histopathology"},{"issue":"5","key":"6934_CR48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/his.13009","volume":"69","author":"EA Rakha","year":"2016","unstructured":"Rakha EA, Ahmed MA, Ellis IO (2016) Papillary carcinoma of the breast: diagnostic agreement and management implications. Histopathology 69(5):862\u2013870","journal-title":"Histopathology"},{"issue":"3","key":"6934_CR49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cjp2.201","volume":"7","author":"M van Seijen","year":"2021","unstructured":"van Seijen M, J\u00f3\u017awiak K, Pinder SE, Hall A, Krishnamurthy S, Thomas JS et al (2021) Variability in grading of ductal carcinoma in situ among an international group of pathologists. J Pathol Clin Res 7(3):233\u2013242","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"6934_CR50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/hyaa235","volume":"51","author":"H Tsuda","year":"2021","unstructured":"Tsuda H, Yoshida M, Akiyama F, Ohi Y, Kinowaki K, Kumaki N et al (2021) Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study. Jpn J Clin Oncol 51(3):434\u2013443","journal-title":"Jpn J Clin Oncol"},{"key":"6934_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2017.04.013","volume":"80","author":"T Onega","year":"2017","unstructured":"Onega T, Weaver DL, Frederick PD, Allison KH, Tosteson ANA, Carney PA et al (2017) The diagnostic challenge of low-grade ductal carcinoma in situ. Euro J Cancer 80:39\u201347","journal-title":"Euro J Cancer"},{"issue":"8","key":"6934_CR52","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.2013.108415","volume":"310","author":"LJ Esserman","year":"2013","unstructured":"Esserman LJ, Thompson IM Jr, Reid B (2013) Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310(8):797\u2013798","journal-title":"JAMA"},{"issue":"6","key":"6934_CR53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJMc1505359","volume":"374","author":"HG Welch","year":"2016","unstructured":"Welch HG, Gorski DH, Albertsen PC (2016) Trends in metastatic breast and prostate cancer. N Engl J Med 374(6):596","journal-title":"N Engl J Med"},{"key":"6934_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.4118","author":"M Osdoit","year":"2022","unstructured":"Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R et al (2022) Association of residual ductal carcinoma in situ with breast cancer recurrence in the neoadjuvant I-SPY2 Trial. JAMA Surg. https:\/\/doi.org\/10.1001\/jamasurg.2022.4118","journal-title":"JAMA Surg"},{"issue":"3","key":"6934_CR55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnci\/djp485","volume":"102","author":"CJ Allegra","year":"2010","unstructured":"Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S et al (2010) National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ september 22\u201324, 2009. J Natl Cancer Inst 102(3):161\u2013169","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6934_CR56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.breast.2013.04.010","volume":"22","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Monti S, Mastropasqua MG (2013) DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast 22(4):431\u2013435","journal-title":"Breast"},{"issue":"1","key":"6934_CR57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10911-022-09517-7","volume":"27","author":"GM Wilson","year":"2022","unstructured":"Wilson GM, Dinh P, Pathmanathan N, Graham JD (2022) Ductal carcinoma in situ: molecular changes accompanying disease progression. J Mammary Gland Biol Neoplasia 27(1):101\u2013131","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"5","key":"6934_CR58","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/path.5199","volume":"247","author":"AE McCart Reed","year":"2019","unstructured":"McCart Reed AE, Kalita-De Croft P, Kutasovic JR, Saunus JM, Lakhani SR (2019) Recent advances in breast cancer research impacting clinical diagnostic practice. J Pathol 247(5):552\u2013562","journal-title":"J Pathol"},{"issue":"7","key":"6934_CR59","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/modpathol.2017.21","volume":"30","author":"JB Pang","year":"2017","unstructured":"Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R et al (2017) Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathol 30(7):952\u2013963","journal-title":"Modern Pathol"},{"issue":"1","key":"6934_CR60","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1038\/s41467-022-30573-4","volume":"13","author":"CA Rebbeck","year":"2022","unstructured":"Rebbeck CA, Xian J, Bornel\u00f6v S, Geradts J, Hobeika A, Geiger H et al (2022) Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. Nat Commun 13(1):3399","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"6934_CR61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10585-017-9868-4","volume":"35","author":"PS Soon","year":"2018","unstructured":"Soon PS, Provan PJ, Kim E, Pathmanathan N, Graham D, Clarke CL et al (2018) Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Clin Exp Metas 35(1\u20132):3\u201313","journal-title":"Clin Exp Metas"},{"issue":"6","key":"6934_CR62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2021.22969","volume":"327","author":"D Capurro","year":"2022","unstructured":"Capurro D, Coghlan S, Pires DEV (2022) Preventing digital overdiagnosis. JAMA 327(6):525\u2013526","journal-title":"JAMA"},{"key":"6934_CR63","first-page":"1","volume":"2021","author":"C Bifulco","year":"2021","unstructured":"Bifulco C, Piening B, Bower T, Robicsek A, Weerasinghe R, Lee S et al (2021) Identifying high-risk breast cancer using digital pathology images. Science 2021:1","journal-title":"Science"},{"issue":"6","key":"6934_CR64","first-page":"1120","volume":"11","author":"L Nicosia","year":"2021","unstructured":"Nicosia L, Latronico A, Addante F, De Santis R, Bozzini AC, Montesano M et al (2021) Atypical ductal hyperplasia after vacuum-assisted breast biopsy: can we reduce the upgrade to breast cancer to an acceptable rate? Diagnostics (Basel, Switzerland). 11(6):1120","journal-title":"Diagnostics (Basel, Switzerland)."},{"issue":"1110","key":"6934_CR65","doi-asserted-by":"crossref","first-page":"20200117","DOI":"10.1259\/bjr.20200117","volume":"93","author":"S Schiaffino","year":"2020","unstructured":"Schiaffino S, Cozzi A, Sardanelli F (2020) An update on the management of breast atypical ductal hyperplasia. Br J Radiol 93(1110):20200117","journal-title":"Br J Radiol"},{"issue":"4","key":"6934_CR66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jphys.2022.09.005","volume":"68","author":"JR Zadro","year":"2022","unstructured":"Zadro JR, O\u2019Keeffe M, Ferreira GE, Traeger AC, Gamble AR, Page R et al (2022) Diagnostic labels and advice for rotator cuff disease influence perceived need for shoulder surgery: an online randomised experiment. J Physiother 68(4):269\u2013276","journal-title":"J Physiother"},{"key":"6934_CR67","unstructured":"DCIS Precision (2022) Clinical trials\u2014DCIS precision 2022. https:\/\/www.dcisprecision.org\/clinical-trials\/. Accessed 27 Oct 2022"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06934-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:55:23Z","timestamp":1683827723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6934"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06934-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}